Jordan-based MS Pharma has agreed to acquire Genepharm, a Europe-based pharmaceutical company, it was reported yesterday.
Financial details of the deal were not revealed. Under the terms of the contract, Genepharm's senior management team will continue to serve the company to expand the business activities. The deal is likely to be completed by the end of this month.
Genepharm is said to integrate advanced R&D capabilities with manufacturing capacity in conventional solids, sterile liquid (oncology) and oncology oral solids. The acquisition of Genepharm is intended to help MS Pharma to expand its geographic footprint, in addition to serving more patients and customers in Europe. MS Pharma's present chronic disease range will be expanded with the addition of Genepharm's products related to cardiovascular, CNS and oncology. The deal will also allow Genepharm to access MS Pharma's manufacturing facilities and products portfolio.
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
ELIAS Animal Health names new chief revenue officer
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval